PRPH2 and non-small cell lung carcinoma: RD2 significantly reduced the viability of NSCLC (A549, H23, and H460) cells with half maximal inhibitory concentrations (IC50) at 108.6 ± 10.82, 103.5 ± 6.08, and 138.3 ± 25.63 μM, respectively (Figure 2a–d), while RD3 reduced cell viability in NSCLC cells (A549, H23, andH460) with the IC50 as more than 200 μM.